AYTU BIOPHARMA, INC. - 10-Q Summary
Business Context and Reporting Period
Company: AYTU BIOPHARMA, INC. (AYTU)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2025 (Second Quarter of Fiscal 2026)
Business Overview: Aytu is a pharmaceutical company focused on central nervous system (CNS) diseases. Following the divestiture of its Consumer Health business in July 2024, the company now operates as a single segment focused on three portfolios: EXXUA (gepirone) for Major Depressive Disorder (MDD), an ADHD Portfolio, and a Pediatric Portfolio. The company successfully launched EXXUA in the second quarter of fiscal 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Net Revenue | $15,165 | $29,053 |
| Gross Profit | $9,624 | $18,810 |
| Gross Margin | 63.5% | 64.7% |
| Net Loss (Continuing Ops) | $(10,584) | $(8,619) |
| Net Loss Per Share (Basic) | $(1.05) | $(0.89) |
| Cash and Cash Equivalents | $30,025 | $30,025 |
| Total Debt (Current + Non-Current) | $11,855 | $11,855 |
| Derivative Warrant Liabilities | $27,337 | $27,337 |
| Operating Cash Flow (6 Months) | N/A | $3,057 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 7% ($1.1M) for the quarter and 11% ($3.7M) for the six months compared to the prior year. This was primarily due to a strategic deemphasis of marketing for the ADHD and Pediatric portfolios to focus on the EXXUA launch. The prior year included a $3.3M revenue increase from a vendor negotiation adjustment that did not recur.
- Significant Non-Cash Loss: The company reported a net loss of $10.6M for the quarter, driven largely by an $8.2M non-cash loss on the remeasurement of derivative warrant liabilities. In the prior year quarter, this line item was a $3.0M gain.
- Expense Reductions: Research and Development (R&D) expenses were $0 for the current period, down from $0.5M in the prior quarter, following the indefinite suspension of clinical development programs. Restructuring costs were also $0, compared to $1.3M in the prior quarter.
- Inventory Write-downs: The company recorded $0.8M in inventory write-downs for the quarter, primarily due to slow-moving products and a shift from branded to generic Adzenys products.
Guidance, Outlook, and Risks
- Strategic Focus: Management is focusing on accelerating commercial growth and achieving positive operating cash flows. EXXUA is the centerpiece of commercial efforts, with the company targeting the $22B MDD market.
- Capital Resources: As of December 31, 2025, the company held $30.0M in cash. In June 2025, the company raised $16.6M in gross proceeds via a common stock and prefunded warrant offering to fund working capital and EXXUA commercialization.
- Debt Obligations: The company has an Eclipse Term Loan ($12.1M principal) and a Revolving Credit Facility ($9.1M drawn). The company remains in compliance with covenants.
- Legal Risks: A patent infringement lawsuit against Granules Pharmaceuticals regarding a generic version of Adzenys is ongoing, with a trial date set for January 11, 2027. The company has successfully obtained a stay on FDA approval for the generic.
- Contingent Payments: The EXXUA Commercialization Agreement includes potential milestone payments ranging from $5M to over $100M and royalties of 28% to 39% of net revenue.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of stock price fluctuations on the $27.3M derivative warrant liability, which caused an $8.2M non-cash loss in the quarter.
- EXXUA Commercialization: Monitor early sales performance of EXXUA ($0.2M revenue in Q2) against the high royalty obligations (up to 39%) and milestone payments owed to Fabre-Kramer.
- Generic Competition: Track the status of the Granules lawsuit and the September 2025 launch of a generic Adzenys product by Teva/Actavis, which may impact the ADHD portfolio revenue.
- Liquidity Runway: Assess the $30M cash balance against operating burn rates and debt service requirements ($1.9M current debt portion) to determine the need for future capital raises.
- Inventory Valuation: Review the $1.1M inventory write-down for the six months to assess the risk of further obsolescence as the company shifts product focus.